Cyclin D1 protein expression and function in human breast cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Cyclin D1 is a cell‐cycle regulator essential for G 1, phase progression and a candidate proto‐oncogene implicated in pathogenesis of several human tumour types, including breast carcinomas. In spite of the accumulating genetic evidence, however, there are no data regarding abundance and properties of the cyclin D1 protein in breast cancer. We now report aberrant nuclear overexpression/accumulation of the cyclin D1 protein in about half of the 170 primary breast carcinoma specimens analyzed by monoclonal antibody immunohistochemistry, indicating that the frequency of cyclin D1 abnormalities may be considerably higher than previously deduced from DNA amplification studies. A comparison of the expression patterns in matched lesions at different stages of tumour progression revealed that the cyclin D1 protein aberration appears to reflect a relatively early event and that, when acquired by a tumour, it is maintained throughout breast cancer progression including metastatic spread. In both tumour tissues and breast cancer cell lines, the abundance of this protein shows characteristic variations consistent with a cell‐cycle oscillation and the peak levels expressed in G 1. In all 7 cell lines whose retinoblastoma (Rb) protein is mutant or complexed to SV40 T antigen, exceptionally low levels of cyclin D1 protein and mRNA were found. Antibody‐mediated and anti‐sense oligonucleotide knockout experiments demonstrate the requirement for the cell‐cycle regulatory function of cyclin D1 in breast cancer lines with single or multiple copies of the gene and reveal the absence of such a requirement in the cell lines with Rb defects. Our data are consistent with the notion that the emerging “Rb‐cyclin D1 pathway” represents a frequent target of oncogenic abnormalities in breast cancer. © 1994 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citationANIMAL CELL CYCLES AND THEIR CONTROL
Norbury, C., & Nurse, P. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.002301 · Cited by 1,274
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Pines, J., & Hunter, T. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.1.1 · Cited by 858
Physical interaction of the retinoblastoma protein with human D cyclins
Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., & Weinberg, R. A. (1993) · Cell · doi:10.1016/0092-8674(93)90137-f · Cited by 744
Xiong, Y., Connolly, T., Futcher, B., & Beach, D. (1991) · Cell · doi:10.1016/0092-8674(91)90100-d · Cited by 685
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Molecular targets of dietary agents for prevention and therapy of cancer
Aggarwal, B. B., & Shishodia, S. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.02.009 · Cited by 1,754
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
“50% of patients with breast cancer.(9) Cyclin D is the catalyst for CDK 4 and 6, and overactivation of CDK 4 and 6 may attenuate senescence and promote cell cycle progression.”
BackgroundThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“These findings appear relevant to human breast cancers where cyclin D1 is frequently overexpressed (Bartkova et al., 1994) and where low levels of p27Kip1 convey a poor prognosis (Catzavelos et al., 1997; Porter et al., 1997; Cariou et al., 1998).”
BackgroundThe protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Minireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
“, while cyclin D1 protein is overexpressed in over 50% of human mammary carcinoma”
BackgroundLin, S.-Y., Xia, W., Wang, J. C., Kwong, K. Y., Spohn, B., Wen, Y., Pestell, R. G., & Hung, M.-C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.060025397 · Cited by 783
Debnath, J., Mills, K. R., Collins, N. L., Reginato, M. J., Muthuswamy, S. K., & Brugge, J. S. (2002) · Cell · doi:10.1016/s0092-8674(02)01001-2 · Cited by 763
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
CDK-Independent Activation of Estrogen Receptor by Cyclin D1
Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., & Michalides, R. J. A. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81879-6 · Cited by 720
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis
Sicinski, P., Donaher, J. L., Geng, Y., Parker, S. B., Gardner, H., Park, M. Y., Robker, R. L., Richards, J. S., McGinnis, L. K., Biggers, J. D., et al. (1996) · Nature · doi:10.1038/384470a0 · Cited by 697
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene
Boehm, J. S., Zhao, J. J., Yao, J., Kim, S. Y., Firestein, R., Dunn, I. F., Sjostrom, S. K., Garraway, L. A., Weremowicz, S., Richardson, A. L., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.052 · Cited by 617
The Role of Prolactin in Mammary Carcinoma
Clevenger, C. V., Furth, P. A., Hankinson, S. E., & Schuler, L. A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0036 · Cited by 545
Wulf, G. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3459 · Cited by 528
GSK-3 as potential target for therapeutic intervention in cancer
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2037 · Cited by 508
Cyclins and cdks in development and cancer: a perspective
Deshpande, A., Sicinski, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 464
Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 437
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Cell-Cycle Control by Physiological Matrix Elasticity and In Vivo Tissue Stiffening
Klein, E. A., Yin, L., Kothapalli, D., Castagnino, P., Byfield, F. J., Xu, T., Levental, I., Hawthorne, E., Janmey, P. A., & Assoian, R. K. (2009) · Current Biology · doi:10.1016/j.cub.2009.07.069 · Cited by 421
Nuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413
Role of Curcumin in Cancer Therapy
Shishodia, S., Chaturvedi, M. M., & Aggarwal, B. B. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2007.04.001 · Cited by 413
Cyclin D1 in Breast Cancer Pathogenesis
Arnold, A., & Papanikolaou, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.064 · Cited by 411
Bulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., Appella, E., & Fornace, A. J. (2004) · Nature Genetics · doi:10.1038/ng1317 · Cited by 409
Cyclin D1 Stimulation of Estrogen Receptor Transcriptional Activity Independent of cdk4†
Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. G., Hinds, P. W., Dowdy, S. F., Brown, M., et al. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5338 · Cited by 392
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 375
Adams, P. D., Sellers, W. R., Sharma, S. K., Wu, A. D., Nalin, C. M., & Kaelin, W. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6623 · Cited by 373
Inhibition of Ras-Induced Proliferation and Cellular Transformation by p16 INK4
Serrano, M., Gómez-Lahoz, E., DePinho, R. A., Beach, D., & Bar-Sagi, D. (1995) · Science · doi:10.1126/science.7809631 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Lukas, J., Bartkova, J., Rohde, M., Strauss, M., & Bartek, J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2600 · Cited by 366
Self-citationCyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
The Molecular Mechanism Governing the Oncogenic Potential of SOX2 in Breast Cancer
Chen, Y., Shi, L., Zhang, L., Li, R., Liang, J., Yu, W., Sun, L., Yang, X., Wang, Y., Zhang, Y., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802917200 · Cited by 358
Mukhopadhyay, A., Banerjee, S., Stafford, L. J., Xia, C., Liu, M., & Aggarwal, B. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206048 · Cited by 353
Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.672-683.2000 · Cited by 347
Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes
Liou, Y.-C., Ryo, A., Huang, H.-K., Lu, P.-J., Bronson, R., Fujimori, F., Uchida, T., Hunter, T., & Lu, K. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032404099 · Cited by 339
Weinstat-Saslow, D., Merino, M. J., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. L., & Steeg, P. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1257 · Cited by 335
Lukas, J., Bartkova, J., & Bartek, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6917 · Cited by 327
Self-citationCyclin D1 and prognosis in human breast cancer
Gillett, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., & Barnes, D. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960422)69:2<92::aid-ijc4>3.0.co;2-q · Cited by 327
Donnellan, R., & Chetty, R. (1998) · Molecular Pathology · doi:10.1136/mp.51.1.1 · Cited by 327
Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins
Liou, Y.-C., Zhou, X. Z., & Lu, K. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.07.001 · Cited by 326
The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer
Tsihlias, M., Kapusta, M., & Slingerland, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.401 · Cited by 319
Parkin and mitophagy in cancer
Bernardini, J. P., Lazarou, M., & Dewson, G. (2017) · Oncogene · doi:10.1038/onc.2016.302 · Cited by 281
Hernandez, L., Fest, T., Cazorla, M., Teruya-Feldstein, J., Bosch, F., Peinado, M., Piris, M., Montserrat, E., Cardesa, A., Jaffe, E., et al. (1996) · Blood · doi:10.1182/blood.v87.8.3351.bloodjournal8783351 · Cited by 275
Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer
Ormandy, C. J., Musgrove, E. A., Hui, R., Daly, R. J., & Sutherland, R. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023033708204 · Cited by 270
Estrogen-Dependent Cyclin E-cdk2 Activation through p21 Redistribution
Planas-Silva, M. D., & Weinberg, R. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.4059 · Cited by 267
Molecular mechanisms of curcumin action: Gene expression
Shishodia, S. (2013) · BioFactors · doi:10.1002/biof.1041 · Cited by 263
Sutherland, R. L., & Musgrove, E. A. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023591.45568.77 · Cited by 258
Overexpression of the Integrin-linked Kinase Promotes Anchorage-independent Cell Cycle Progression
Radeva, G., Petrocelli, T., Behrend, E., Leung-Hagesteijn, C., Filmus, J., Slingerland, J., & Dedhar, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13937 · Cited by 257
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis
Welcsh, P. L., Lee, M. K., Gonzalez-Hernandez, R. M., Black, D. J., Mahadevappa, M., Swisher, E. M., Warrington, J. A., & King, M.-C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062181799 · Cited by 256
PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells
Ryo, A., Liou, Y.-C., Wulf, G., Nakamura, M., Lee, S. W., & Lu, K. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5281-5295.2002 · Cited by 253
The role of Rho GTPases in disease development
Boettner, B., & Van Aelst, L. (2002) · Gene · doi:10.1016/s0378-1119(02)00426-2 · Cited by 229
Aggarwal, P., Lessie, M. D., Lin, D. I., Pontano, L., Gladden, A. B., Nuskey, B., Goradia, A., Wasik, M. A., Klein-Szanto, A. J. P., Rustgi, A. K., et al. (2007) · Genes & Development · doi:10.1101/gad.1586007 · Cited by 132
“Cyclin D1 overexpression occurs in carcinomas of the esophagus, head and neck, breast, and colon, as well as certain B-cell lymphomas (Bartkova et al. 1994a,b, 1995; Gillett et al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000;…”
BackgroundControlling the master—upstream regulation of the tumor suppressor LKB1
Kullmann, L., & Krahn, M. P. (2018) · Oncogene · doi:10.1038/s41388-018-0145-z · Cited by 75
Metadata
- Authors
- Bartkova, J., Lukas, J., Müller, H., Lützhøt, D., Strauss, M., & Bartek, J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-05
- Volume
- 57
- Issue
- 3
- Pages
- 353-361
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2119040192
- Cited by
- 509
- References
- 32
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.